Clinical studies of gatifloxacin for infections in internal medicine

Japanese Journal of Chemotherapy

Volumn 50, Issue 10, 2002, Pages 646-673

  Saito, Atsushi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gatifloxacin

Indexed keywords

AMPICILLIN; CLARITHROMYCIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; METICILLIN; OFLOXACIN; PENICILLIN G; SPARFLOXACIN;

ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BIOEQUIVALENCE; BRONCHIECTASIS; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC BRONCHITIS; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PENETRATION; DRUG SPUTUM LEVEL; GASTROINTESTINAL TOXICITY; HUMAN; INFORMATION PROCESSING; INTERNAL MEDICINE; META ANALYSIS; PARTITION COEFFICIENT; PNEUMONIA; RASH; RESPIRATORY TRACT INFECTION; REVIEW; STOMATITIS; SUPERINFECTION; URTICARIA;

EID: 0036815020     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Hosaka M, Yasue T, Fukuda H, et al.: In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 36: 2108-2117, 1992
2. Wakabayashi E, Mitsuhashi S: Invitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 38: 594-601, 1994
3. Ishida K, Kaku M, Irifune K, et al.: In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae. J. Antimicrob. Chemother. 34: 875-883, 1994
4. Hosaka M, Kinoshita S, Toyama A, et al.: Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J. Antimicrob. Chemother. 36: 293-301, 1995
5. Kato N, Kato H, Tanakah-Bandoh K, et al.: Comparative in vitro and in vivo activity of AM-1155 against anaerobic bacteria. J. Antimicrob. Chemother. 40: 631-637, 1997
6. Tomioka H, Saito H, Sato K, et al.: Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, Sparfloxacin and Ofloxacin. Antimicrob. Agents Chemother. 37: 1259-1263, 1993
7. Tomizawa H, Tateda K, Miyazaki S, et al.: Antibacterial activity of AM-1155 against penicillin -resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 41: 103-106, 1998
8. Miyashita N, Niki Y, Kishimoto T, et al.: In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob. Agents Chemother. 41: 1331-1334, 1997
9. Miyara T, Gaja M, Saito A, et al.: Antimicrobial activity of AM-1155 against Legionella. 3 rd western pacific congress on chemotherapy and infectious diseases, Bali, Indonesia, 1992
10. Japanese Source. Gatifloxacin 26: 1651-1654, 1998
11. Wakabayashi E, Kitamura Y, Kuninishi Y, et al.: Possible Role of Drug Photodegradation in Fluoroquinolone (FQ)-Induced Phototoxicity in Mice. 41st ICAAC, Chicago, Abstracts: A-48, 2001
12. Japanese source. 43 AM-1155, 1995
13. Nakashima M, Uematsu T, Kosuge K, et al.: Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. 39: 2635-2640, 1995
14. Japanese source. gatifloxacin 47 (S-2): 260-276, 1999
15. Japanese source. gatifloxacin 47 (S-2): 277-291, 1999
16. Japanese source. gatifloxacin 47 (S-2): 419-437, 1999
17. Japanese source. gatifloxacin levofloxacin 47: 712-733, 1999
18. Japanese source. gatifloxacin levofloxacin 47: 734-757, 1999
19. Japanese source. gatifloxacin 47: 623-631, 1999
20. Takei M, Fukuda H, Yasue T, et al.: Inhibitory Activities of Gatifloxacin (AM-1155), a Newly Developed Fluoroquinolone, against Bacterial and Mammalian Type II Topoisomerase. Antimicrob. Agents Chemother. 42: 2678-2681, 1998
21. Takei M, Fukuda H, Kishii R, et al.: Target Preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45: 3544-3547, 2001
22. Fukuda H, Hiramatsu K: Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43: 410-412, 1999
23. Japanese source. Levofloxacin Ofloxacin Chemotherapy 40 (S-3): 121-146, 1992
24. Japanese source. sparfloxacin (SPFX) ofloxacin (OFLX) Chemotherapy 39 (S-4): 429-453, 1991
25. Japanese source. T-3262 (tosufloxacin tosilate) ofloxacin Chemotherapy 37: 1086-1118, 1989
26. Japanese source. Levofloxacin Ofloxacin Chemotherapy 40 (S-3): 97-120, 1992
27. Japanese source. sparfoxacin (SPFX) ofloxacin (OFLX) Chemotherapy 39 (S-4): 405-428, 1991
28. Gothelf S, Ehrhardt A F, Wikler M A, et al.: Clinical Efficacy of Gatifloxacin in Infectious Due to Penicillin Resistant Streptococcus pneumoniae: Results from the Tequin Clinical Experience Study (TeqCES). 41 st ICAAC, Chicago, Abstracts: L-871, 2001
29. Japanese source. Prontosil Ciprofloxacin Therapeutic Research 17: 1760-1766, 1996
30. Japanese source. 30 DL-8280 1982
31. Japanese source. 32 BAY 9867 (Ciprofloxacin), 1984
32. Japanese source. 34 T-3262, 1987
33. Japanese source. 38 (2), sparfloxacin (AT-4140), 1990
34. Japanese source. 39 Lecofloxacin (DR-3355), 1991
35. Japanese source. No.83, 1987
36. Japanese source. No.127, 1994
37. Japanese source NSAIDs No.98, 1989
38. Japanese source. theophylline p.359-364, 1991
39. Japanese source. No.117, 1992
40. Japanese source. No.128, 1994
41. Japanese source. QT 49: 229-235, 2001
42. Iannini P B, Circiumaru I: Gatifloxacin-induced QTc prolongation and ventricular tachycardia. Pharmacotherapy 21: 361-362, 2001
43. Japanese source. Gatifloxacin 50: 719-729, 2002